74 unchanged sentences
Certificate of Incorporation of Provectus Biopharmaceuticals, Inc., as amended (incorporated by reference to Exhibit 3.1 of the Company’s annual report on Form 10-K filed with the SEC on March 31, 2017).
−Removed: Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s current report on Form 8-K filed with the SEC on June 24, 2021).
−Removed: Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s current report on Form 8-K filed with the SEC on June 25, 2024).
−Removed: Certificate of Designation of Preferences, Rights and Limitations of Series D-1 Convertible Preferred Stock (as amended by the Certificate of Amendment, dated March 30, 2022) (incorporated by reference to Exhibit 3.4 of the Company’s quarterly report on Form 10-Q filed with the SEC on May 12, 2022).
−Removed: Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 of the Company’s current report on Form 8-K filed with the SEC on June 25, 2024).
+Added: Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (as amended by the Certificate of Amendment, dated June 24, 2024 and the Certificate of Amendment, dated January 30, 2026).
+Added: Certificate of Designation of Preferences, Rights and Limitations of Series D-1 Convertible Preferred Stock (as amended by the Certificate of Amendment, dated March 30, 2022, the Certificate of Amendment dated June 24, 2024, and the Certificate of Amendment, dated January 30, 2026).
Bylaws of Provectus Biopharmaceuticals, Inc.
48 unchanged sentences
Indemnification Agreement between the Company and Dominic Rodrigues, dated April 3, 2017 (incorporated by reference to Exhibit 10.3 of the Company’s current report on Form 8-K filed with the SEC on April 4, 2017).
−Removed: Indemnification Agreement between the Company and Ed Pershing, dated April 19, 2018 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on April 24, 2018).
−Removed: Indemnification Agreement between the Company and Jack Lacey, MD, dated April 19, 2018 (incorporated by reference to Exhibit 10.2 of the Company’s current report on Form 8-K filed on April 24, 2018).
−Removed: Indemnification Agreement between the Company and Webster Bailey, effective as of July 20, 2020 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on July 16, 2020).
+Added: Indemnification
+Added: Agreement between the Company and Ed Pershing, dated April 19, 2018 (incorporated by reference to Exhibit 10.1 of the
+Added: Company’s current report on Form 8-K filed with the SEC on April 24, 2018).
+Added: Indemnification
+Added: Agreement between the Company and Jack Lacey, MD, dated April 19, 2018 (incorporated by reference to Exhibit 10.2 of the
+Added: Company’s current report on Form 8-K filed with the SEC on April 24, 2018).
+Added: Indemnification
+Added: Agreement between the Company and Webster Bailey, effective as of July 20, 2020 (incorporated by reference to Exhibit 10.1 of the
+Added: Company’s current report on Form 8-K filed with the SEC on July 16, 2020).
Code of Ethics (incorporated by reference to Exhibit 14 of the Company’s annual report on Form 10-K filed with the SEC on March 16, 2011).
+Added: Letter from Marcum dated April 16, 2025 (incorporated by reference to Exhibit 16.1 to the Company’s current report on Form 8-K filed with the SEC on April 16, 2025).
Provectus Biopharmaceuticals, Inc.
−Removed: Securities Trading Policy
−Removed: Subsidiaries of the Company.
+Added: Securities Trading Policy (incorporated by reference to Exhibit 19 of the Company’s annual report on Form 10-K filed with the SEC on March 28, 2025).
+Added: Subsidiaries of the Company (incorporated by reference to Exhibit 21 of the Company’s annual report on Form 10-K filed with the SEC on March 28, 2025).
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) of the Securities Exchange Act of 1934.
16 unchanged sentences
Dominic Rodrigues
−Removed: President (principal executive officer)
+Added: (principal executive officer)
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
11 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.